Similar sites
Category
N/AGlobal Rank
N/ARank in 1 month
208.4KEstimate Value
N/Ael imcyc, a.c. es una asociación no lucrativa dedicada a la investigación, enseñanza y difusión de las técnicas de aplicación del cemento y del concreto.
#carbonatacion del concreto
#concreto permeable
#cemento resistente a los sulfatos
#concreto celular pdf
#resistencia del concreto
#patologia del concreto
#losa de concreto
#fisuras en muros de concreto
#losas de concreto
#concreto celular
#cemex concretos
#cemex monterrey
#concreto premezclado cemex
#impercem
#historia del cemento
#prefabricados de concreto
#muros tilt up
#constanza ontiveros valdés
#ntc concreto 2017
#normas tecnicas complementarias
#reparacion de grietas en muros de mamposteria
#concreto mr 45
#concreto
#arquitectura
#instituto
#mexicano
#construcción
#ingeniería
#internacional
#resistencia a la flexion del concreto
Category
Automotive IndustryGlobal Rank
N/ARank in 1 month
42.5KEstimate Value
N/Ayour import parts solution
#switch
#import
#fuel injection
#solution
#auto parts
Malware Scan Info
Macafee Check :
Email address with imcyse.com
2. [email protected]
3. [email protected]
4. [email protected]
5. [email protected]
6. [email protected]
7. [email protected]
8. [email protected]
Recent Searched Sites
Cgsportsphotos.com (17 seconds ago) / US
Derby-hotel-barcelona.hotelmix.it (7 seconds ago) / US
Brunopinheiro.me (2 mins ago) / US
Liteoutdoors.com (2 mins ago) / US
Delplocken.se (48 seconds ago) / US
Morromar-apartments-puerto-del-carmen.hotelmix.es (4 mins ago) / US
Pbcsportsnetwork.com (25 seconds ago) / US
Realhomemadeturbo.com (41 seconds ago) / US
Iseekfeet.com (52 seconds ago) / US
Alihit.ru (1 mins ago) / RU
Barrelhorseworldnetwork.com (1 mins ago) / US
Duki.biz (1 mins ago) / RU
Imcyse.com (1 seconds ago) / FR
M.hantvn.com (28 seconds ago) / US
Troyka-hotel-saint-petersburg.nochi.com (2 mins ago) / US
Hukseflux.com (28 seconds ago) / NL
Modern-dogs.de (44 seconds ago) / DE
Hatenatome.com (1 mins ago) / JP
Dbqfair.com (3 seconds ago) / US
Pro-patinage.com (1 mins ago) / FR
Domain Informations
Imcyse.com lookup results from whois.ovh.com server:
- Domain created: 2010-11-10T14:33:31Z
- Domain updated: 2023-11-01T07:04:26Z
- Domain expires: 2024-11-10T14:33:31Z 0 Years, 169 Days left
- Website age: 13 Years, 196 Days
- Registrar Domain ID: 1624779378_DOMAIN_COM-VRSN
- Registrar Url: http://www.ovh.com
- Registrar WHOIS Server: whois.ovh.com
- Registrar Abuse Contact Email: [email protected]
- Registrar Abuse Contact Phone: +33.972101007
- Name server:
- DNS10.OVH.NET
- NS10.OVH.NET
Domain Provider | Number Of Domains |
---|---|
godaddy.com | 680706 |
namecheap.com | 224184 |
networksolutions.com | 165998 |
tucows.com | 138228 |
publicdomainregistry.com | 88771 |
whois.godaddy.com | 62305 |
enomdomains.com | 58590 |
namesilo.com | 49131 |
cloudflare.com | 48249 |
gmo.jp | 46138 |
register.com | 39207 |
fastdomain.com | 38533 |
ionos.com | 33836 |
name.com | 32521 |
wildwestdomains.com | 32329 |
net.cn | 31283 |
registrar.amazon.com | 30188 |
dynadot.com | 27527 |
key-systems.net | 27174 |
Host Informations
Host name | cluster006.ovh.net |
IP address | 213.186.33.17 |
Location | France |
Latitude | 48.8582 |
Longitude | 2.3387 |
Timezone | Europe/Paris |
Port Scanner (IP: 213.186.33.17)
Spam Check (IP: 213.186.33.17) › Dnsbl-1.uceprotect.net:
› Dnsbl-2.uceprotect.net:
› Dnsbl-3.uceprotect.net:
› Dnsbl.dronebl.org:
› Dnsbl.sorbs.net:
› Spam.dnsbl.sorbs.net:
› Bl.spamcop.net:
› Recent.dnsbl.sorbs.net:
› All.spamrats.com:
› B.barracudacentral.org:
› Bl.blocklist.de:
› Bl.emailbasura.org:
› Bl.mailspike.org:
› Bl.spamcop.net:
› Cblplus.anti-spam.org.cn:
› Dnsbl.anticaptcha.net:
› Ip.v4bl.org:
› Fnrbl.fast.net:
› Dnsrbl.swinog.ch:
› Mail-abuse.blacklist.jippg.org:
› Singlebl.spamgrouper.com:
› Spam.abuse.ch:
› Spamsources.fabel.dk:
› Virbl.dnsbl.bit.nl:
› Cbl.abuseat.org:
› Dnsbl.justspam.org:
› Zen.spamhaus.org:
Site Inspections
Websites Listing
We found Websites Listing below when search with imcyse.com on Search Engine
Imcyse SA | LinkedIn
Imcyse SA | 2,896 followers on LinkedIn. Pioneering the development of Imotopes™ to prevent, stop and potentially cure autoimmune diseases | Imcyse is a …
Linkedin.comDA: 16 PA: 20 MOZ Rank: 36
Imcyse Company Profile - Craft
Imcyse is a developer of active specific immunotherapies for the treatment and prevention of severe chronic diseases caused by disruptions of the immune system. Its active immunotherapy technology platform allows it to destroy locally the immune cells involved in the destruction of the diseased organ. Show more
Craft.coDA: 8 PA: 11 MOZ Rank: 20
Imcyse SA - Company Profile and News - Bloomberg …
Imcyse SA operates as a clinical-stage biotech company. The Company develops active specific immunotherapies for the treatment and prevention of severe chronic diseases, as …
Bloomberg.comDA: 17 PA: 28 MOZ Rank: 47
ImCyse Company Profile: Valuation & Investors | PitchBook
ImCyse General Information Description. Developer of therapeutic vaccines designed to offer treatment of multiple sclerosis and diabetes. The company's vaccines help to destroy locally the immune cells involved in the destruction of the diseased organ for the generation of a new type of T-cell called cytolytic CD4 and prevent the immunogenic responses that weaken the efficiency …
Pitchbook.comDA: 13 PA: 27 MOZ Rank: 43
Imcyse - Pagan Research
Imcyse's mission is to develop a radically new approach for the treatment of severe, chronic autoimmune diseases. Imcyse was founded in 2011 as a spin-off of the Catholic University of Leuven Imcyse. The company is headquartered in Liège, Belgium. Imcyse's unique technology platform can address a wide range of autoimmune and immunologic ...
Paganresearch.ioDA: 16 PA: 15 MOZ Rank: 35
ImCyse S.A. Information | ImCyse S.A. Profile
Imcyse is a clinical-stage biotech company headquartered in Liège, Belgium, created in 2010 as a spin-off of the Catholic University of Leuven (KULeuven). Numerous proof of concept studies have been completed in animal models for type 1 diabetes, multiple sclerosis, myasthenia gravis, allergic diseases, prevention of graft rejection and blocking of immunogenicity to viral vectors. …
Rocketreach.coDA: 14 PA: 35 MOZ Rank: 54
Imotopes: An Inmunotherapy animation | 3DforScience
ABOUT IMOTOPES. CLIENT: Imcyse is a clinical-stage biotech company created in 2010 as a spin-off of the Catholic University of Leuven, aiming to develop the next generation of therapeutic biologics. SERVICE: At 3DforScience we turned the client illustrations into easily understandable 3D scientific animation explaining their disruptive approach through an …
3dforscience.comDA: 16 PA: 32 MOZ Rank: 54
Imcyse to Present Late-Breaking Abstract of its ImotopeTM-Based …
Imcyse's approach, sustained over time, helps to prevent and treat diseases with no current therapeutic alternative and to potentially cure patients without impairing immune defense. The company has established proof of concept in several indications and has completed its first clinical trial in type 1 diabetes with promising results. Beyond type 1 diabetes, Imcyse is …
Accesswire.comDA: 18 PA: 50 MOZ Rank: 43
Imcyse | CipherBio
Last Funding Round. $25.8M. Founded: 2010 About. Developing disease specific immune therapies to treat severe, chronic auto-immune, inflammatory, allergic, infectious diseases and tumors. Funding Timeline. request_quote Submit a Deal. Created with Highcharts 9.2.2. Date Funding Founded Series B Series B Funding total 01/01/2010 01/01/2011 01/01 ...
Cipherbio.comDA: 17 PA: 29 MOZ Rank: 54
Jobs with Imcyse - BioSpace
About Imcyse. Imcyse is a clinical-stage biotech company headquartered in Liège, Belgium, created in 2010 as a spin-off of the Catholic University of Leuven (KULeuven). Numerous proof of concept studies have been completed in animal models for type 1 diabetes, multiple sclerosis, myasthenia gravis, allergic diseases, prevention of graft rejection and blocking of …
Biospace.comDA: 16 PA: 25 MOZ Rank: 50
Imcyse Stock / Share Price, Funding Rounds, Valuation and ... - Craft
Imcyse's latest funding round in June 2019 was reported to be $39.2 m. In total, Imcyse has raised $46.6 m
Craft.coDA: 8 PA: 19 MOZ Rank: 37
Imcyse Raises €21.3M for Therapies in MS, Other Autoimmune …
Imcyse has raised €21.3 million ($25.8 million) in funding to advance its innovative immunotherapy platform for the treatment of multiple sclerosis …
Multiplesclerosisnewstoday.comDA: 30 PA: 50 MOZ Rank: 39
Imcyse « European Biotech Investor Days 2021 - Trout Access
Imcyse: Developer of therapeutic vaccines designed to offer treatment of multiple sclerosis and diabetes. The company's vaccines help to destroy locally the immune cells involved in the destruction of the diseased organ for the generation of a new type of T-cell called cytolytic CD4 and prevent the immunogenic responses that weaken the efficiency of chronic therapies, …
Soleburytroutaccess.comDA: 23 PA: 50 MOZ Rank: 38
Imcyse Company Profile | Liège, Belgium | Competitors, Financials ...
Company Description: Imcyse is located in Liège, Belgium and is part of the Scientific Research and Development Services Industry. Imcyse has 30 employees at this location and generates $98,629 in sales (USD). Key Principal: Vincent Guy André Brichard ...
Dnb.comDA: 11 PA: 50 MOZ Rank: 37
Imcyse - Funding, Financials, Valuation & Investors - Crunchbase
Funding. Imcyse has raised a total of €55.9M in funding over 4 rounds. Their latest funding was raised on Feb 17, 2021 from a Series B round. Imcyse is funded by 10 investors. Biogenosis and Epimède SA are the most recent investors.
Crunchbase.comDA: 18 PA: 39 MOZ Rank: 71
Imcyse
Imcyse's mission is to develop a radically new approach for the treatment of severe, chronic autoimmune diseases. Imcyse was founded in 2011 as a spin-off of the Catholic University of Leuven Imcyse. The company is headquartered in Liège, Belgium. Imcyse's unique technology platform can address a wide range of autoimmune and immunologic diseases.
Paganresearch.ioDA: 16 PA: 15 MOZ Rank: 46
Imcyse closes €21.3m Series B as new partner Pfizer takes equity …
Imcyse has raised €21.3m in a Series B round, which includes an equity purchase by new partner Pfizer. The Belgian company plans to use funding to advance its novel therapeutic candidates for severe autoimmune conditions such as type 1 diabetes, multiple sclerosis and rheumatoid arthritis. Bedoret notes Imcyse's Imotope products do this by ...
Pharmaceutical-technology.comDA: 33 PA: 45 MOZ Rank: 94
Imcyse | flanders.bio
Imcyse develops active targeted immune therapies (ImotopesÔ) that locally inhibit the immune cells involved in the destruction of the diseased organ. The targeted approach and memory effect of the Imcyse technology help to prevent and cure diseases with no current therapeutic alternative, caused by disruptions of the immune system without impairing the …
Flanders.bioDA: 12 PA: 27 MOZ Rank: 56
Imcyse Enters into Research Collaboration and License Agreement …
(PFE) for Imcyse's Rheumatoid Arthritis (RA) program based on the Company's ImotopeTM technology. Following the successful completion of a research collaboration initiated in 2017, the companies have entered into such license agreement to develop ImotopesTM to potentially treat RA.
Ca.sports.yahoo.comDA: 19 PA: 50 MOZ Rank: 32
Domains Expiration Date Updated
Site | Provider | Expiration Date |
---|---|---|
wccm2022.org | onamae.com | 5 Years, 83 Days |
jamjamnews.com | hostinger.com | 38 Days |
storitallcabinets.net | networksolutions.com | 225 Days |
middletownlifemagazine.com | godaddy.com | 206 Days |
learnog.com | namecheap.com | 128 Days |
blogdesire.com | namesilo.com | 57 Days |
backtothemovies.com | godaddy.com | 52 Days |
michaelbarnes.info | godaddy.com | 132 Days |
evansville-diocese.org | namebright.com | 235 Days |
cookinghits.net | networksolutions.com | 89 Days |